Supernus Pharmaceuticals Bundle
Who Really Owns Supernus Pharmaceuticals?
Navigating the complex world of biopharmaceutical investments requires a deep understanding of company ownership. Supernus Pharmaceuticals, a key player in the central nervous system (CNS) market, has a fascinating ownership structure that has evolved significantly since its founding. Understanding Supernus Pharmaceuticals SWOT Analysis can also offer valuable insights.
From its inception in 2005, Supernus Pharmaceuticals has seen shifts in its ownership, impacting its strategic direction and financial performance. Knowing who owns Supernus is crucial for investors looking at Supernus stock and understanding the company's future. This analysis will explore the current landscape, revealing the major shareholders and their influence, and offering insights into the company's leadership team and its overall market position.
Who Founded Supernus Pharmaceuticals?
The story of Supernus Pharmaceuticals begins with its founder, Jack A. Khattar, who has been at the helm since its inception in 2005. His prior experience, notably as President and CEO of Shire Laboratories Inc., laid the groundwork for the company's focus on central nervous system (CNS) disorders. The early ownership structure reflects a strategic blend of founder leadership and venture capital backing, crucial for the company's initial growth phase.
Supernus Pharmaceuticals' formation involved acquiring assets from Shire Laboratories Inc., setting the stage for its product development and formulation expertise. This strategic move, combined with early financial support from venture capital firms, was pivotal in establishing Supernus as a key player in the pharmaceutical industry. The early ownership structure was shaped by significant venture capital investments.
Early backing from venture capital firms was critical for Supernus Pharmaceuticals. New Enterprise Associates (NEA) and OrbiMed Advisors were among the initial investors. In February 2006, Supernus secured an additional $17.5 million in financing, completing its Series A funding with a total of $45 million. This round included continued participation from NEA and the addition of Abingworth Management.
Early Investors and Key Figures
The initial ownership of Supernus Pharmaceuticals was significantly influenced by venture capital firms like NEA and OrbiMed Advisors. Charles W. Newhall, III, co-founder of NEA, joined Supernus's Board of Directors in 2005, underscoring NEA's early influence. While specific equity splits are not publicly detailed, the involvement of these venture capital firms indicates a substantial early ownership stake. Understanding the early ownership structure is essential for anyone researching Supernus Pharmaceuticals' target market and its overall company profile.
- Jack A. Khattar founded Supernus Pharmaceuticals in 2005 and has served as CEO since its inception.
- NEA and OrbiMed Advisors were key early investors, providing crucial funding at the company's formation.
- The Series A funding, completed in 2006, totaled $45 million, with NEA and Abingworth Management as key participants.
- Charles W. Newhall, III, from NEA, joined Supernus's Board of Directors in 2005, reflecting the venture firm's influence.
Supernus Pharmaceuticals SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
How Has Supernus Pharmaceuticals’s Ownership Changed Over Time?
The evolution of Supernus Pharmaceuticals' ownership structure began with its initial public offering (IPO) on May 1, 2012. The company listed on the Nasdaq Global Market under the ticker symbol 'SUPN,' with an initial offering price of $5.00 per share. At the IPO, 10,000,000 shares of common stock were sold. As of June 13, 2025, the market capitalization has grown to $1.79 billion, representing a 1,240.11% increase since the IPO.
The ownership landscape has shifted significantly since the IPO. Early investors like New Enterprise Associates (NEA) and Abingworth Management, through their affiliates, played a role in the IPO, collectively purchasing 6,600,000 shares of common stock. Today, institutional investors hold a substantial portion of the company. The shift towards broader institutional and public ownership has likely influenced the company's strategic focus, emphasizing market performance and investor relations.
| Key Event | Date | Impact on Ownership |
|---|---|---|
| Initial Public Offering (IPO) | May 1, 2012 | Transition from private to public ownership; establishment of initial shareholder base. |
| Institutional Investment Growth | Ongoing | Increased influence of institutional investors on company strategy and market performance. |
| Individual Insider Holdings | Early 2025 | Significant holdings by key executives, aligning their interests with company performance. |
As of May 31, 2025, institutional ownership of Supernus Pharmaceuticals stands at 106.34% of the total shares outstanding. Key institutional shareholders include BlackRock, Inc., Vanguard Group Inc, Armistice Capital, LLC, and Dimensional Fund Advisors Lp. Individual shareholders also hold significant stakes. For example, Peter J. Barris owns 11.86 million shares, representing 21.18% of the company in early 2025, with a value of approximately $380.69 million. Other notable individual insiders include Scott D. Sandell (21.00% or 11.76M shares) and Forest Baskett (20.98% or 11.75M shares).
Key Takeaways on Supernus Ownership
The ownership of Supernus Pharmaceuticals has evolved significantly since its IPO, with a shift towards substantial institutional ownership. This shift has likely influenced the company's focus on market performance and investor relations.
- Institutional investors hold a significant portion of the company's shares.
- Key executives and insiders maintain substantial ownership stakes.
- The company's strategic direction is influenced by both institutional and individual shareholders.
- For further insights, you can refer to this article about Supernus Pharmaceuticals analysis.
Supernus Pharmaceuticals PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
Who Sits on Supernus Pharmaceuticals’s Board?
The current Board of Directors of Supernus Pharmaceuticals includes key figures with diverse backgrounds. Jack A. Khattar, the founder, President, and CEO, has been a Director since 2005. Charles W. Newhall, III, a co-founder of NEA, a venture capital firm and early investor in Supernus, also joined the board in 2005. Carrolee Barlow, MD, PhD, and George Gemayel, PhD, bring scientific and industry expertise, having been appointed in June 2018 and 2015, respectively. The board also includes independent members, ensuring robust governance oversight.
These board members contribute to the strategic direction and oversight of the company. Their combined experience in pharmaceuticals, finance, and scientific research is crucial for guiding the company's growth and navigating the complexities of the healthcare industry. The presence of independent directors ensures that the board operates with objectivity and in the best interests of all shareholders. The composition of the board reflects a balance of experience and perspectives, essential for effective corporate governance.
| Board Member | Role | Year Joined |
|---|---|---|
| Jack A. Khattar | Founder, President, and CEO, Director | 2005 |
| Charles W. Newhall, III | Director | 2005 |
| Carrolee Barlow, MD, PhD | Director | 2018 |
| George Gemayel, PhD | Director | 2015 |
As of April 22, 2025,
Supernus Pharmaceuticals
had a total of 55,989,623 shares of common stock outstanding, with each share carrying one vote. Significant voting power is concentrated among certain shareholders. Insiders like Peter J. Barris, Scott D. Sandell, and Forest Baskett collectively hold a substantial percentage of the company, influencing voting outcomes. Institutional investors, such as BlackRock, Inc. and Vanguard Group Inc., also wield considerable voting power due to their large shareholdings. The company's governance structure is regularly detailed in its SEC filings.
Voting Power and Ownership
The voting structure at
Supernus Pharmaceuticals
is primarily one-share-one-vote, but significant shareholders hold considerable influence. Key insiders and institutional investors have substantial voting power due to their large shareholdings. The company's governance details are available in its SEC filings.- Key insiders hold significant voting power.
- Institutional investors have considerable influence.
- Governance details are disclosed in SEC filings.
- The total number of shares outstanding is 55,989,623 as of April 2025.
Supernus Pharmaceuticals Business Model Canvas
- Complete 9-Block Business Model Canvas
- Effortlessly Communicate Your Business Strategy
- Investor-Ready BMC Format
- 100% Editable and Customizable
- Clear and Structured Layout
What Recent Changes Have Shaped Supernus Pharmaceuticals’s Ownership Landscape?
In recent years, Supernus Pharmaceuticals has maintained active engagement with the market, consistently releasing financial results and communicating with investors. The company's financial reports for Q4 and the full year of 2024 were released on February 25, 2025, with the Q1 2025 results scheduled for release on May 6, 2025. For 2024, the company reported revenues of $661.82 million, an increase of 8.94% compared to the previous year. Earnings saw a significant increase, rising by 5512.84% to $73.87 million.
Ownership trends show a dynamic landscape. As of May 2025, institutional investor holdings remained largely stable at 108.33%. Mutual funds increased their holdings from 83.31% to 83.62%. Insider holdings saw a slight decrease, moving from 2.46% to 2.43% in May 2025. Some hedge funds adjusted their positions in Q4 2024, with ARMISTICE CAPITAL, LLC and POLAR CAPITAL HOLDINGS PLC reducing their stakes, while WOODLINE PARTNERS LP increased its shares. Insider selling has been noted over the past six months, including President and CEO Jack A. Khattar selling 250,000 shares for an estimated $9.12 million.
| Metric | Q4 2024 | Full Year 2024 |
|---|---|---|
| Revenue | Not Specified | $661.82 million |
| Earnings | Not Specified | $73.87 million |
| Institutional Ownership (May 2025) | 108.33% | 108.33% |
| Mutual Fund Ownership (May 2025) | 83.31% | 83.62% |
| Insider Ownership (May 2025) | 2.46% | 2.43% |
The company continues to participate in investor conferences, such as the 2025 Jefferies Global Healthcare Conference in June 2025 and the Barclays Global Healthcare Conference in March 2025, indicating ongoing efforts to engage with the investment community. These interactions, along with regular SEC filings, provide transparency regarding the company's financial health and shifts in ownership. Supernus Pharmaceuticals also announced the FDA approval of ONAPGO™ (apomorphine hydrochloride) for Parkinson's Disease in February 2025, with a planned launch in the second quarter of 2025, which could influence future ownership trends.
Key Developments
The company reported a revenue increase of 8.94% for 2024.
Ownership Changes
Insider holdings slightly decreased, while mutual fund ownership increased.
Upcoming Events
The company will present at the Jefferies Global Healthcare Conference in June 2025.
Product Approval
FDA approved ONAPGO™ (apomorphine hydrochloride) for Parkinson's Disease.
Supernus Pharmaceuticals Porter's Five Forces Analysis
- Covers All 5 Competitive Forces in Detail
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
Related Blogs
- What are Mission Vision & Core Values of Supernus Pharmaceuticals Company?
- What is Competitive Landscape of Supernus Pharmaceuticals Company?
- What is Growth Strategy and Future Prospects of Supernus Pharmaceuticals Company?
- How Does Supernus Pharmaceuticals Company Work?
- What is Sales and Marketing Strategy of Supernus Pharmaceuticals Company?
- What is Brief History of Supernus Pharmaceuticals Company?
- What is Customer Demographics and Target Market of Supernus Pharmaceuticals Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.